Eva Ehrnrooth - Nov 4, 2021 Form 3 Insider Report for IO Biotech, Inc. (IOBT)

Role
Chief Medical Officer
Signature
/s/ Brian Burkavage, Attorney-in-Fact for Eva Ehrnrooth
Stock symbol
IOBT
Transactions as of
Nov 4, 2021
Transactions value $
$0
Form type
3
Date filed
11/4/2021, 09:32 PM
Next filing
Mar 22, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IOBT Warrants (Right to Buy) Nov 4, 2021 Common Stock 9.8K $16.86 Direct F1, F2
holding IOBT Warrants (Right to Buy) Nov 4, 2021 Common Stock 56.4K $12.64 Direct F2, F3
holding IOBT Warrants (Right to Buy) Nov 4, 2021 Common Stock 5.12K $19.62 Direct F2, F3
holding IOBT Warrants (Right to Buy) Nov 4, 2021 Common Stock 47.4K $12.64 Direct F2, F3
holding IOBT Warrants (Right to Buy) Nov 4, 2021 Common Stock 183K $12.64 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1 These Warrants vest in 25% annual increments starting on December 31, 2018, subject to the reporting person's continued service through the applicable vesting date.
F2 Warrants expire in annual increments on the fifth anniversary of the vesting date.
F3 These Warrants vest in 1/48 monthly increments after the May 27, 2021 vesting commencement date, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause or by the reporting person within 24 months of a change of control.
F4 These Warrants vest in 1/48 monthly increments after October 15, 2021 vesting commencement date, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause or by the reporting person within 24 months of a change of control.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney